Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Diastolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids probably leads to lower diastolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Ever diagnosed as asthmatic by 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in ever diagnosed as asthmatic by 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Neonates with developing BPD
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic steroids (low certainty).
1 finding from 1 review
Hyperglycaemia · Neonates with developing BPD
Inhaled steroids showed no clear difference in hyperglycaemia compared with systemic steroids (low certainty).
1 finding from 1 review
Hypertension · Neonates with developing BPD
Inhaled steroids may leads to lower hypertension compared with systemic steroids (low certainty).
1 finding from 1 review
General conceptual ability (GCA) score at 7 years The test has a standardisation mean of 100 and SD of 15 · Neonates with developing BPD
Inhaled steroids showed no clear difference in general conceptual ability (GCA) score at 7 years The test has a… compared with systemic steroids (moderate certainty).
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Systolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in systolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review